Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences

  Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global
  Healthcare Conferences

Business Wire

ARDSLEY, N.Y. -- February 19, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present
at the RBC Capital Markets and the Citi 2013 Global Healthcare conferences in
February.

Jane Wasman, President, International and General Counsel, will present at the
RBC Capital Markets Healthcare Conference on Tuesday, February 26 at 2:35 pm
ET at The New York Palace Hotel in New York. A live audio webcast of the
presentation can be accessed under “Investor Events” in the Investor section
of the Acorda website at www.acorda.com, or you may use the link:

http://www.veracast.com/webcasts/rbc/healthcare2013/97112243.cfm

Ron Cohen, Acorda’s President and Chief Executive Officer, will present at the
Citi 2013 Global Healthcare Conference on Wednesday, February 27 at 1:30 pm ET
at the Hilton New York Hotel in New York. A live audio webcast of the
presentation can be accessed under “Investor Events” in the Investor section
of the Acorda website at www.acorda.com, or you may use the link:

http://www.veracast.com/webcasts/citigroup/healthcare2013/04308188.cfm

Please log in approximately 5 minutes before the scheduled time of the
presentations to ensure a timely connection. Archived versions of these
webcasts will be available until March 26 and March 27, 2013, respectively, on
the Investors section of www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies
that restore function and improve the lives of people with MS, spinal cord
injury and other neurological conditions.

Acorda markets AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg, in
the United States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking speed.
AMPYRA is marketed outside the United States as FAMPYRA^® (prolonged-release
fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland
Limited.

The Company also markets ZANAFLEX CAPSULES^® (tizanidine hydrochloride) and
Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis, Inc.
under its agreement with Acorda.

Acorda has an industry-leading pipeline of novel neurological therapies. The
Company is developing Diazepam Nasal Spray for treatment of certain epileptic
seizures. It is also studying AMPYRA to improve a range of functional
impairments caused by MS, as well as its potential for use in other
neurological conditions, including cerebral palsy and post-stroke deficits. In
addition, Acorda is developing clinical stage compounds AC105 for acute
treatment of spinal cord injury, GGF2 for treatment of heart failure and
rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS.GGF2 is
also being investigated in preclinical studies as a treatment for neurological
conditions such as stroke and spinal cord injury. Chondroitinase, an enzyme
that encourages nerve plasticity in spinal cord injury, is in preclinical
development.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including our ability to successfully market and
sell Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development programs,
including Diazepam Nasal Spray or any other acquired or in-licensed programs;
we may not be able to complete development of, obtain regulatory approval for,
or successfully market Diazepam Nasal Spray or other products under
development; the occurrence of adverse safety events with our products; delays
in obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our collaboration
partnerBiogen Idecin connection therewith; competition, including the impact
of generic competition on Zanaflex Capsules revenues; failure to protect our
intellectual property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and the
ability to obtain additional financing to support our operations. These and
other risks are described in greater detail inAcorda Therapeutics'filings
with the Securities & Exchange Commission.Acordamay not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
release.

Contact:

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com
 
Press spacebar to pause and continue. Press esc to stop.